Navigation Links
Covance To Present At The William Blair 32nd Annual Growth Stock Conference
Date:6/8/2012

PRINCETON, N.J., June 8, 2012 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today announced that it will present at the William Blair 32nd Annual Growth Stock Conference on Tuesday, June 12, 2012 at 9:50 a.m. (ET).  Investors may access a live webcast of the presentation at www.covance.com.  In order to register and download any necessary software, please log on 10 minutes early.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 11,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release (and in the webcast announced in this press release), which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue, earnings growth, and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories, fluctuations in currency exchange rates, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company To Present At The William Blair Growth Stock Conference
2. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
3. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
4. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
7. Body Monitors Deliver Better Weight Loss Results at Half the Cost: Study to Be Presented at ACSM Meeting
8. Regeneron Announces June 2012 Investor Conference Presentations
9. Isis Pharmaceuticals to Present at the Goldman Sachs 33rd Annual Global Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
11. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of ... their families to thrive on nutrition support. To celebrate its ... new site has a fresh new look with improved organization to create ... ... ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral drug ... the Israel Securities Authority to dual-list its common stock on ... commence trading on the TASE on July 12, 2017 under ... the Company, it is expected that Oramed will be included ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
Breaking Medicine Technology:
(Date:7/23/2017)... ... , ... Scientists from the University of Exeter reported this month ... equivalent to a medium-paced run for pre-menopausal women, or a slow jog for post-menopausal ... spine care, I understand the importance exercise can play on improving bone health. Although ...
(Date:7/23/2017)... Fla. (PRWEB) , ... July 23, 2017 , ... ... M.D., has joined Florida Pain Relief Group – Melbourne, a practice owned by ... board certification in interventional pain management, Dr. Stern also is certified in pediatrics, ...
(Date:7/22/2017)... ... July 22, 2017 , ... The arthroscopic superior capsule ... opportunity to return to sports and jobs that require heavy physical work, as ... Annual Meeting in Toronto, Ontario, Canada. , “We studied 100 patients ...
(Date:7/21/2017)... Orange Park, FL (PRWEB) , ... July 21, ... ... that provides insurance management assistance and financial planning services to families and business ... in a charity event that promises to provide support to area adults with ...
(Date:7/21/2017)... ... , ... Hospital M&A activity slowed in the second quarter of 2017, according ... to 23 in the second quarter, up 15% from the 20 publicly announced acquisitions ... in the year-ago second quarter. Only four of the transactions disclosed a purchase price ...
Breaking Medicine News(10 mins):